Trials / Completed
CompletedNCT05418608
Novel in Vivo Synaptic Imaging in Experienced Meditators
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 28 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To utilize positron emission tomography (PET) imaging to characterize the distribution of (aka \[11C\]APP311at the Yale PET Center) in cortical and subcortical areas in experienced meditators compared to non-meditating controls.
Detailed description
The investigators will conduct a PET study of the novel SV2A imaging tracer \[11C\]UCB-J in participants, to characterize the distribution of \[11C\]UCB-J in cortical and subcortical areas in experienced meditators compared to non-meditating controls. A total of up to 20 subjects will complete the study. Subjects will undergo one PET scan with \[11C\]UCB-J. Each subject will also undergo one MRI scan for anatomical identification of brain regions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radiotracer | A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans. |
Timeline
- Start date
- 2022-04-21
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
- First posted
- 2022-06-14
- Last updated
- 2024-07-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05418608. Inclusion in this directory is not an endorsement.